Phentolamine Mesylate Patent Expiration
Phentolamine Mesylate is Used for reversal of soft-tissue anesthesia following intraoral local anesthetic injection. It was first introduced by Novartis Pharmaceuticals Corp
Phentolamine Mesylate Patents
Given below is the list of patents protecting Phentolamine Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ryzumvi | US12201615 | Methods and compositions for treatment of mydriasis | Dec 25, 2039 | Famygen Life Sci |
| Ryzumvi | US11400077 | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | Oct 25, 2039 | Famygen Life Sci |
| Ryzumvi | US12201616 | Methods and compositions for treatment of mydriasis | Oct 25, 2039 | Famygen Life Sci |
| Ryzumvi | US10278918 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
| Ryzumvi | US10772829 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
| Ryzumvi | US11090261 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
| Ryzumvi | US11844858 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
| Ryzumvi | US9795560 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | Jan 31, 2034 | Famygen Life Sci |
| Oraverse | US7575757 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Apr 21, 2025
(Expired) | Septodont Holding |
| Oraverse | US7569230 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Oct 17, 2023
(Expired) | Septodont Holding |
| Oraverse | US7229630 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Jun 20, 2023
(Expired) | Septodont Holding |
| Oraverse | US6764678 | Local anesthetic methods and kits |
May 11, 2021
(Expired) | Septodont Holding |
| Oraverse | US6872390 | Local anesthetic methods and kits |
May 11, 2021
(Expired) | Septodont Holding |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Phentolamine Mesylate's patents.
Latest Legal Activities on Phentolamine Mesylate's Patents
Given below is the list recent legal activities going on the following patents of Phentolamine Mesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Mar, 2024 | US10772829 |
| Electronic Review Critical
| 02 Feb, 2024 | US11844858 |
| Email Notification Critical
| 20 Dec, 2023 | US11844858 |
| Recordation of Patent Grant Mailed Critical
| 19 Dec, 2023 | US11844858 |
| Patent Issue Date Used in PTA Calculation Critical
| 19 Dec, 2023 | US11844858 |
| Recordation of Patent eGrant | 19 Dec, 2023 | US11844858 |
| Mail Patent eGrant Notification | 19 Dec, 2023 | US11844858 |
| Patent eGrant Notification | 19 Dec, 2023 | US11844858 |
| Email Notification Critical
| 30 Nov, 2023 | US11844858 |
| Issue Notification Mailed Critical
| 29 Nov, 2023 | US11844858 |
Phentolamine Mesylate's Family Patents
